Janus Henderson Group PLC lowered its stake in GlycoMimetics Inc (NASDAQ:GLYC) by 1.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,169,490 shares of the biotechnology company’s stock after selling 15,040 shares during the period. Janus Henderson Group PLC owned 2.71% of GlycoMimetics worth $16,841,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. WINTON GROUP Ltd purchased a new position in shares of GlycoMimetics during the third quarter worth $186,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of GlycoMimetics during the second quarter worth $189,000. Voya Investment Management LLC purchased a new position in shares of GlycoMimetics during the second quarter worth $205,000. Quantitative Systematic Strategies LLC purchased a new position in shares of GlycoMimetics during the second quarter worth $264,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of GlycoMimetics during the second quarter worth $268,000.
Several research analysts recently issued reports on GLYC shares. Cowen reissued a “buy” rating on shares of GlycoMimetics in a report on Monday, August 13th. ValuEngine raised shares of GlycoMimetics from a “buy” rating to a “strong-buy” rating in a report on Monday, October 8th. Stifel Nicolaus reissued a “buy” rating and set a $24.00 target price on shares of GlycoMimetics in a report on Sunday, August 12th. BidaskClub cut shares of GlycoMimetics from a “hold” rating to a “sell” rating in a report on Thursday, August 30th. Finally, Roth Capital set a $35.00 target price on shares of GlycoMimetics and gave the stock a “buy” rating in a report on Monday, November 5th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $28.00.
GLYC stock opened at $10.55 on Friday. GlycoMimetics Inc has a one year low of $10.43 and a one year high of $26.05.
GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Friday, November 2nd. The biotechnology company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.03. Equities analysts forecast that GlycoMimetics Inc will post -1.16 earnings per share for the current year.
In related news, SVP John L. Magnani sold 14,200 shares of the firm’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $14.01, for a total transaction of $198,942.00. Following the sale, the senior vice president now owns 86,593 shares in the company, valued at $1,213,167.93. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP John L. Magnani sold 25,000 shares of the firm’s stock in a transaction on Thursday, October 18th. The shares were sold at an average price of $14.01, for a total transaction of $350,250.00. Following the sale, the senior vice president now owns 86,593 shares in the company, valued at approximately $1,213,167.93. The disclosure for this sale can be found here. 43.80% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “GlycoMimetics Inc (GLYC) Shares Sold by Janus Henderson Group PLC” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/12/08/glycomimetics-inc-glyc-shares-sold-by-janus-henderson-group-plc.html.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.
See Also: Derivative
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.